Aldeyra Therapeutics entered into an agreement with AbbVie to modify terms related to their collaboration on a new drug, with costs for launch activities capped at mid-single-digit millions, and the FDA has accepted their application for a new dry eye disease treatment, with a decision expected by April 2, 2025.